DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee

• Co exa Pha macy to dispe se compou ded BPC-157, TB-500, KPV, MOTS-c, Epitalo a d Semax i acco da ce with HHS’ ece tly updated E fo ceme t Disc etio Policy
• Bulk d ug substa ce access facilitates 3PL divisio ‘s ag eeme ts with ma ufactu e s seeki g to sell i to Co exa Health’s 6,500+ I depe de t Pha macy Netwo k (IPN) outlet
• Health Lives He e mobile app to facilitate IPN safety data epo ti g

TAMPA, FL / ACCESS Newswi e / Novembe 2, 2026 / DataMeds AI, I c. (“DataMeds SI,” “DataMEDS” o the “Compa y”)(NASDAQ:MEDS), a healthca e compa y that i teg ates its health i fo matio tech ology a d physical i f ast uctu e with its Ei stei Rx^™ a tificial i tellige ce platfo m a d Pha macyChai ^™ blockchai -e abled sma t co t acts platfo m, today a ou ced that its pha macy-focused subsidia y Co exa Health has e te ed i to a ag eeme t fo comme cial supply to bulk d ug substa ce a d API of six (6) peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalo a d Semax, togethe the “Six Peptides”) ecomme ded by the U.S. Food a d D ug Admi ist atio ‘s (FDA) Pha macy Compou di g Adviso y Committee (PCAC) at its July 23-24, 2026 meeti g. Co exa Pha macy i te ds to begi dispe di g complia t compou ded peptide p esc iptio s fo patie ts i Novembe 2026.

DataMEDS i te ds to leve age the Health Lives He e mobile applicatio to help collect a d epo t safety data, i acco da ce with U.S. Health a d Huma Se vices’ (HHS) E fo ceme t Disc etio Policy (EDP) published i the Fede al Registe o Octobe 30, 2026. The U.S. compou di g pha macy ma ket is expected to g ow f om $18 billio i 2025 to ove $31 billio by 2035, acco di g to P ecede ce Resea ch.

“HHS’ ece t policy cha ges allow Co exa Pha macy to dispe se compou ded ve sio s of these Six Peptides a d also allows ou dist ibutio divisio to leve age its thi d-pa ty logistics (3PL) capabilities to help bulk d ug substa ce a d API to complia tly ma age thei supply via ou st ategically located wa ehouse i Lakela d, Flo ida,” said Ge ald Commissio g, I te im Co-CEO of DataMEDS. “Th ough elatio ships with eme gi g ma ufactu e s of complia t d ug substa ce o API, helpi g to imp ove access to the Six Peptides fo the 503A compou di g pha macies withi ou etwo k of 6,500+ i depe de t pha macies. This ep ese ts a sig ifica t oppo tu ity fo Co exa to give physicia s a egulated, pha macy-compou ded optio i place of the u egulated esea ch-use-o ly p oducts sold o li e. We believe that ma y g ay ma ket patie ts would p efe to pu chase thei peptides f om a lice sed pha macy.

The Six Peptides a e compou ded d ugs, a e ot FDA-app oved a d have ot bee evaluated by FDA fo safety o efficacy.

About DataMEDS AI

DataMEDS AI, I c. (NASDAQ:MEDS), fo me ly Wellgistics Health, I c., is a healthca e compa y focused o the ve tical i teg atio of tech ology, pha macy, pha maceutical-adjace t a d telemedici e busi ess u its th ough its health i fo matio tech ology platfo ms to delive a bette expe ie ce fo co sume s a d p ovide s. Headqua te ed i Tampa, Fla., DataMEDS i co po ates its Ei stei Rx^™ a tificial i tellige ce platfo m a d Pha macyChai ^™ blockchai -e abled sma t co t acts platfo m i to the Health Lives He e mobile applicatio f om Tollo Health, LLC, a d its pha macy- elated Co exa Health subsidia y p ovides pha macy dispe si g a d pha macy- elated se vices, i cludi g dist ibutio of p oducts developed by Tollo Health. DataMEDS also ow s Helomics Co po atio , a Pittsbu gh, PA-based comme cial cli ical molecula diag ostics labo ato y focused o the ChemoFx^® Assay chemothe apy selectio diag ostics test that aims to help o cologists make chemothe apy t eatme t decisio s. Lea mo e at https://datamedsai.com.

About Tollo Health

Tollo Health, LLC is a healthca e compa y comme cializi g p op ieta y medical foods a d dieta y suppleme ts a d, th ough TolloBio, developi g biopha maceutical ca didates, alo gside its Health Lives He e mobile applicatio . Co exa Health, a subsidia y of DataMeds AI, I c., dist ibutes select Tollo Health medical foods a d dieta y suppleme ts u de a wholesale dist ibutio a a geme t.

Fo wa d-Looki g Stateme ts

This p ess elease co tai s fo wa d-looki g stateme ts withi the mea i g of the P ivate Secu ities Litigatio Refo m Act of 1995. These stateme ts a e based o ma ageme t’s cu e t expectatio s a d a e ot p edictio s of actual pe fo ma ce. Fo wa d-looki g stateme ts i clude, without limitatio , stateme ts ega di g FDA o HHS could cha ge o withd aw the e fo ceme t disc etio policy; competitio f om u egulated esea ch-use-o ly p oducts; FDA’s fi al decisio s o the bulks list; state boa d of pha macy ules; elia ce o a si gle supplie a d its quality; ste ile compou di g complia ce; adve se eve ts a d p oduct liability; physicia p esc ibi g dema d; uptake i the pha macy etwo k; the lau ch timi g (Novembe 2026); the white-label a a geme t a d elia ce o the pa t e pha macy; the Compa y’s ability to mai tai complia ce with Nasdaq listi g sta da ds; a d the Compa y’s liquidity, capital esou ces a d ability to fu d ope atio s. Actual esults may diffe mate ially f om those exp essed o implied i these fo wa d-looki g stateme ts due to a umbe of isks a d u ce tai ties, i cludi g those desc ibed u de “Risk Facto s” i the Compa y’s most ece t A ual Repo t o Fo m 10-K a d subseque t fili gs with the Secu ities a d Excha ge Commissio . Reade s a e cautio ed ot to place u due elia ce o these fo wa d-looki g stateme ts, which speak o ly as of the date of this p ess elease. The Compa y u de takes o obligatio to update o evise a y fo wa d-looki g stateme ts, except as equi ed by law.

DataMEDS AI Media Co tactJames Lambe t, Vice P eside t, Rube stei Public Relatio s212.805.3024 | jlambe t@ ube stei p .com

DataMEDS AI I vesto Co tactIR@datamedsai.com

SOURCE: DataMEDS AI, I c.

View the o igi al p ess elease o ACCESS Newswi e